<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>NRM, relapse, chronic GvHD, and survival</italic>: NRM did not differ significantly between treatment arms (
 <xref rid="t3-1030522" ref-type="table">Table 3</xref>), with a 2-year cumulative incidence of 14% (A, 95% CI, 5–26) 
 <italic>vs</italic>. 16% (B, 95% CI, 7–29) 
 <italic>vs</italic>. 6.4% (C, 95% CI, 1.6–16; 
 <italic>P</italic>=0.62) (
 <xref ref-type="fig" rid="f2-1030522">Figure 2C</xref>). Relapse did not differ significantly between treatment arms, with a 2-year cumulative incidence of 32% (A, 95% CI, 18–46) 
 <italic>vs</italic>. 32% (B, 95% CI, 19–47) 
 <italic>vs</italic>. 38% (C, 95% CI, 24–52; 
 <italic>P</italic>=0.74) (
 <xref ref-type="fig" rid="f2-1030522">Figure 2D</xref>). The 2-year cumulative incidence of cGvHD did not differ significantly between treatment arms, at 59% (A) 
 <italic>vs</italic>. 60% (B) 
 <italic>vs</italic>. 55% (C; 
 <italic>P</italic>=0.66) (
 <xref ref-type="fig" rid="f3-1030522">Figure 3A</xref>). For five patients, cGvHD occurred after documented hematologic malignancy relapse (A, 1; B, 2; C, 2) and these were included in the estimation of cumulative incidence of cGvHD. Two had early IS taper, none received DLI. The 2-year PFS did not differ significantly between treatment arms, at 54% (A) 
 <italic>vs</italic>. 52% (B) 
 <italic>vs</italic>. 55% (C; 
 <italic>P</italic>=0.95) (
 <xref ref-type="fig" rid="f3-1030522">Figure 3B</xref>). The 2-year OS did not differ significantly between treatment arms, at 61% (A) 
 <italic>vs</italic>. 62% (B) 
 <italic>vs</italic>. 62% (C; 
 <italic>P</italic>=0.98) (
 <xref ref-type="fig" rid="f3-1030522">Figure 3C</xref>). The composite 2-year GRFS endpoint did not differ significantly between treatment arms, at 11% (A) 
 <italic>vs</italic>. 12% (B) 
 <italic>vs</italic>. 8% (C; 
 <italic>P</italic>=0.53) (
 <xref ref-type="fig" rid="f3-1030522">Figure 3D</xref>).
</p>
